ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Healthy, volunteers of either sex, at least 18 years of age or older
- Females of childbearing potential submitted to a urine pregnancy test and had negative results at Day 1 and at the final visit and also was using an effective method of birth control (e.g. abstinence, implants, injectables, oral contraceptives, intrauterine contraceptive devices or double barrier) or agreed to use an effective method of birth control prior to becoming sexual active
- Subjects were of any skin type or race providing their degree of pigmentation did not interfere with making readings of skin reactions
- Subjects were willing to follow the study procedures and complete the study
- Written informed consent was obtained
- Subject with any skin disease that would have in any way confounded interpretation of
the study results. Atopic dermatitis/eczema, psoriasis or chronic asthma were excluded
- Subject was pregnant or nursing
- Subject had a history of sensitivity to any component of any of the formulations
- Use of chronic medications (such as antihistamines, corticosteroids, analgesics and
anti-inflammatories) for one week before and during the study
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Bryan, Texas
- Bryan, Texas
- Chihuahua,
- Guadalajara,
- Guadalajara,
- Mexico City,
- Mexico City,
- Mexico City,
- Monterrey,
- Monterrey,
- Toluca,
- Birmingham, Alabama
- San Francisco, California
- Albuquerque, New Mexico
- New York, New York
- Austin, Texas
- Bryan, Texas
- San Antonio, Texas
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Cumulative Irritation Test | |||
Official Title ICMJE | 21-day Cumulative Irritation Test | |||
Brief Summary | The purpose of this study is to determine the cumulative irritation potential of the products listed by the Sponsor. | |||
Detailed Description | Healthy, adult volunteers of either sex will be patched on his/her back with AN2690 Solution 2.5%, AN2690 Solution 5%, AN2690 Solution 7.5%, AN2690 Solution Vehicle and Sodium Laurel Sulfate 0.5% over the course of 21 consecutive days. After 24 hours, the patches are to be removed and the site evaluated using a five-point scale for irritation. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 1 | |||
Study Design ICMJE | Masking: None (Open Label) Primary Purpose: Other | |||
Condition ICMJE | Onychomycosis | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 37 | |||
Original Actual Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | February 19, 2007 | |||
Actual Primary Completion Date | February 19, 2007 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00680095 | |||
Other Study ID Numbers ICMJE | AN2690-ONYC-101 C3371011 ( Other Identifier: Alias Study Number ) | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | April 2019 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |